Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

GELTAMO (Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea) is a leading Spanish cooperative research group dedicated to the advancement of diagnosis and treatment for lymphomas and hematopoietic stem cell transplantation. Functioning as a non-profit scientific association, the group coordinates a nationwide network of hematologists and researchers to conduct multicenter clinical trials and biological studies. GELTAMO plays a critical role in the Spanish healthcare landscape by developing clinical guidelines and evaluating innovative therapies, including immunotherapies and targeted agents. The organization collaborates extensively with international research bodies and pharmaceutical partners to improve clinical outcomes and survival rates for patients with hematologic malignancies. Their work encompasses a broad range of research from early-phase clinical trials to large-scale observational studies and registry management.